GBS vs. CODX, AKLI, RVP, MODD, XAIR, FEMY, NMTC, MDAI, CTCX, and ICU
Should you be buying GBS stock or one of its competitors? The main competitors of GBS include Co-Diagnostics (CODX), Akili (AKLI), Retractable Technologies (RVP), Modular Medical (MODD), Beyond Air (XAIR), Femasys (FEMY), NeuroOne Medical Technologies (NMTC), Spectral AI (MDAI), Carmell (CTCX), and SeaStar Medical (ICU). These companies are all part of the "surgical & medical instruments" industry.
Co-Diagnostics (NASDAQ:CODX) and GBS (NYSE:GBS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
GBS has lower revenue, but higher earnings than Co-Diagnostics. GBS is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Co-Diagnostics had 1 more articles in the media than GBS. MarketBeat recorded 12 mentions for Co-Diagnostics and 11 mentions for GBS. GBS's average media sentiment score of -0.17 beat Co-Diagnostics' score of -0.37 indicating that Co-Diagnostics is being referred to more favorably in the media.
Co-Diagnostics presently has a consensus target price of $2.00, suggesting a potential upside of 83.49%. Given GBS's higher probable upside, equities analysts plainly believe Co-Diagnostics is more favorable than GBS.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 2.4% of Co-Diagnostics shares are held by insiders. Comparatively, 0.3% of GBS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
GBS has a net margin of 0.00% compared to GBS's net margin of -582.36%. GBS's return on equity of -42.35% beat Co-Diagnostics' return on equity.
Co-Diagnostics received 273 more outperform votes than GBS when rated by MarketBeat users.
Co-Diagnostics has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.
Summary
Co-Diagnostics beats GBS on 10 of the 15 factors compared between the two stocks.
Get GBS News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
